Osteologix Inc

(OTC: OLGX)

Industry: Specialty Retailers
On the web: http://www.osteologix.com
Employees: 3

Osteologix, Inc. was established as a United States subsidiary of Osteologix A/S in October 2004. Osteologix A/S was formed in Denmark on June 16, 2003 as Nordic Bone A/S. On November 18, 2004 Nordic Bone changed its name to Osteologix A/S. On May 24, 2006, Osteologix A/S became a subsidiary of the United States company Osteologix, Inc. The principal activity of the Company is the development of innovative pharmaceuticals for the treatment and prevention of diseases of bone and joint tissues. The Company's development program is currently focused on pharmaceutical use of strontium compounds for metabolic diseases. This development program builds on the previous experience with other strontium salts, which have been demonstrated clinically to reduce vertebral as well as non vertebral fracture rate and to increase bone mineral density. Studies performed in animals, as well as histological and biomarker assessments of samples from human subjects treated with strontium ranelate, support the theory that strontium salts have a unique mechanism of action on bone metabolism in that they reduce bone resorption while maintaining or increasing the formation of new bone. This results in a systemic improvement in bone strength and quality. The Company's lead product candidate, NB S101, is in clinical development for treatment of osteoporosis. NB S101 is a once-daily oral tablet delivery formulation. Studies carried out with another salt form of strontium known as strontium ranelate as well as earlier studies with other strontium salts suggest that ionic strontium has an ability to decrease resorption of bone while maintaining or increasing formation of new bone. This has also been established for the Company's compound strontium malonate, NB S101, in preclinical studies. Recently, the Company completed the first phase I studies of the pharmacokinetic properties of NB S101. The studies revealed that strontium is well absorbed from NB S101 formulated in tablets, and also demonstrated that a one gram tablet dose of NB S101 results in the same level of strontium in human serum as the Protelos sachet containing two grams of strontium ranelate. The Company is subject to numerous federal, state and local laws relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.